Pharmacist Program

As of February 26, 2015

TIME	SESSION #	SESSION	COURSE DIRECTOR(S)	NOTES	CREDITS
7:30am – 5:15pm	220	Kidney Transplantation 2015	Fuad Shihab, MD, FNKF Milagros Samaniego, MD	• '0	7.5
7:30am –4:30pm	222	CKD Management Along the Continuum: From Predialysis to Policy Supported by an educational grant from AstraZeneca	Charmaine Lok, MD, MSc, FNKF Christopher Chan, MD, FRCPC	• '@}	7.25
7:30am – 12:30pm	621	Critical Care in Nephrology – Part 1	Mandy Trolinger, MS, RD, PA-C, FNKF	• '@	4.25
8:00am – 6:00pm	223	Glomerular Diseases: Updates on Pathogenesis and Treatment	Fernando Fervenza, MD, PhD FNKF Michael Choi, MD, FNKF	• '@}	7.5
1:00pm – 6:00pm	624	Critical Care in Nephrology – Part 2	Mandy Trolinger, MS, RD, PA-C, FNKF	• '0)	4.25

## Thursday, March 26

TIME	SESSION #	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am	800	Breakfast Symposium: Hyperkalemia and Emerging Treatments in Chronic Kidney Disease Supported by an educational grant from ZS Pharma	Chair: Csaba Kovesdy, MD	<b>10</b> 1	1.5
		Clinical Settings of Hyperkalemia	Csaba Kovesdy, MD	-	
		Limitations in the Acute and Chronic Treatment of Hyperkalemia	Jerry Yee, MD, FNKF	-	
		Emerging Treatment Options for Hyperkalemia	Wolfgang Winkelmayer, MD, ScD, MPH, FASN		
6:00am – 7:45am 801	801	Breakfast Symposium: Getting Ahead of Metabolic and Mineral Disturbances in the Management of CKD-MBD: A Focus on Management Strategies Supported by an educational grant from Sanofi-aventis U.S.	Chair: Ellie Kelepouris, MD, FAHA	<b>'O</b> ł	1.5
		Pathophysiology of CKD-MBD and Cardiovascular Consequences	Rajnish Mehrotra, MD, FNKF	-	
		Assessment of Dietary Interventions to Mitigate Risk	Kathleen Hill Gallant, PhD, RD, CD	-	
		Medical Management of Altered Calcium and Phosphorus in the Patient with CKD-MBD	Ellie Kelepouris, MD, FAHA	-	
8:00am – 9:30am	261	Management of Patients with Glomerular Disease	Chairs: Debbie Gipson, MD, FNKF, and Fernando Fervenza, MD, PhD, FNKF		1.5
		Optimizing Outcomes in IgA Nephropathy	Michael Choi, MD, FNKF	-	
		Integrating Progress in Membranous Nephropathy into Clinical Practice	David Salant, MD	-	
		Getting it Right in ANCA Vasculitis: The Right Test and the Right Treatment for the Right Patient	Patrick Nachman, MD		
8:00am – 9:30am	262	Long-Term Outcomes in Kidney Transplantation	Chairs: Fuad Shihab, MD, FNKF, and Ajay Israni, MD	_	1.5
		Pathology and Causes of Long-Term Graft Loss	Arjang Djamali, MD		
		Recurrent Disease in the Renal Allograft	David Cohen, MD	_	
		Dealing with Threats to Patient Survival	Donald Hricik, MD		
9:30am – 10:00am		Break			
10:00am – 11:30am	263	Controversy: Age-Stratified Thresholds of GFR for Defining CKD	Chair: Kamyar Kalantar-Zadeh, MD, PhD, MPH, FNKF		1.5
		Pro: A Proposal to Modify the 2012 KDIGO Guidelines	Richard Glassock, MD	_	
		Con: The 2012 KDIGO Guidelines Got It Right	Andrew Levey, MD		
10:00am – 11:30am	662	Hypertensionthe Full Truth		_	1.5
		Multi-Drug Resistant Hypertension	Debbie Cohen, MD	_	
		Case Studies in Difficult to Treat Hypertension	Raymond Townsend, MD, FAHA		
10:00am – 11:30am	288	Pursuit of High Value Care for Persons with Kidney Diseases	Shari Ling, MD		1.5

### Pharmacist Program

As of February 26, 2015

11:30am – 12:00pm		Break			
12:00pm – 2:00pm	802	Lunch Symposium: What Clinicians Need to Know About How Biosimilars Will Change the Treatment of Chronic Kidney Disease	Chair: Jay Wish, MD	<b>'@</b> }	1.5
		Supported by an educational grant from Hospira			
		Biosimilars Regulation and Development in the United States	Edward Li, PharmD		
		Treating Anemia with Biosimilars: Exploring Risks and Benefits	Francesco Locatelli, MD		
		Operationalizing the Use of Biosimilar ESAs in the U.S.	Jay Wish, MD		
12:00pm – 2:00pm	230	Workshop: Hypertension in the CKD Population – Case-Based Presentation	Chairs: Debbie Cohen, MD, and Raymond Townsend, MD, FAHA	• °C	2.0
		Diagnosis and Management of Hyperaldosteronism	Raymond Townsend, MD, FAHA		
		Diagnosis and Management of Hypertension in	Debbie Cohen, MD		
		Pheochromocyoma			
		Management of the Patient with Supine Hypertension and Orthostatic Hypotension	Raymond Townsend, MD, FAHA	•	
		Management of Hypertension in the Transplant Patient	Simin Goral, MD		
		Management of the Patient with an Adrenal Incidentaloma	Debbie Cohen, MD		
		and Hypertension	·		
12:00pm – 2:00pm 2	231	Workshop: What Do You Know about Glomerular Disease?	Chairs: Patrick Nachman, MD, and Agnes Fogo, MD	• 101	2.0
		Case Presentations and Discussion	Agnes Fogo, MD Sanjeev Sethi, MD, PhD Michael Choi, MD, FNKF Patrick Nachman, MD		
12:00pm – 2:00pm	233	Workshop: Comparative Effectiveness Research and Patient- Centered Outcomes Research: Generating Evidence for Kidney Care	Chair: Wolfgang Winkelmayer, MD, ScD, MPH, FASN	• 101	2.0
		What is Comparative Effectiveness Research and Why Do We Need it in Nephrology?	Wolfgang Winkelmayer, MD, ScD, MPH, FASN		
		A Primer on Methods in Comparative Effectiveness Research	Steven Brunelli, MD		
		Brave New World: Patient-Centeredness and Stakeholder Panels	Francesca Tentori, MD		
		Pragmatic Clinical Trials	Laura Dember, MD		
2:00pm – 2:30pm		Break			
2:30pm – 3:30pm	265	NKF Presidential Address: Improving CKD Patient Health – We Have to Do Betterand We Can	Jeffrey Berns, MD, FNKF		1.0
		Shaul G. Massry Distinguished Lecture: The Anion Gap – An Enduring Concept: 1923 to 2015	Michael Emmett, MD, MACP		
3:30pm – 4:00pm		Break			
4:00pm – 5:30pm	665	To Dose Or Not to Dose			1.5
		Top 10 Nephrotoxic Drugs	Amy Barton Pai, PharmD, BCPS, FASN, FCCP		
		Drug Controversies in CKD	Cheryl Gilmartin, PharmD		
4:00pm – 5:30pm	267	What's New with KDOQI®?	Chair: Michael Rocco, MD		1.5
		2014 KDOQI Hemodialysis Adequacy Update	Thomas Depner, MD		
		How to Write a Hemodiafiltration Prescription and How to Monitor Therapy	Raymond Vanholder, MD		
		The KDOQI Nutrition Update: A Unique Partnership with the American Academy of Nutrition and Dietetics	T. Alp Ikizler, MD		
		A Multidisciplinary KDOQI Vascular Access Update	Charmaine Lok, MD, MSc, FNKF		
6:00pm – 7:30pm		Opening Ceremonies and Reception in the		Ĩ	1.0*
		Exhibit Hall – Visit Posters/Exhibits		1	

### Pharmacist Program

As of February 26, 2015

7:30pm – 9:30pm	803	Dinner Symposium: Iron-Based Phosphate Binders: Clinical Implications of Novel Therapy Supported by an educational grant from Keryx Biopharmaceuticals, Inc.	Chair: Kevin Martin, MB, BCh, FACP	<b>io</b> ì	1.5
		Hyperphosphatemia and the Failing Kidney	Kevin Martin, MB, BCh, FACP		
		Phosphate Binders in Hemodialysis	Diana Jalal, MD	-	
		Benefits Beyond? Ferric Citrate and Anemia Management in ESRD: Newest Evidence	Kausik Umanath, MD	-	
		Case Study: Challenges in Management of Hyperphosphatemia	All Faculty	-	
7:30pm – 9:30pm	804	Dinner Symposium: Utilizing Alternative Approaches to Achieve Uric Acid Target Levels Across a Multidisciplinary Team	Chair: Jay Wish, MD	<b>'O</b> ł	1.5
		Supported by an educational grant from Takeda		_	
		Physiologic Basis for Hyperuricemic Gout and the Kidney's Role	Jay Wish, MD		
		Is There a Role for Screening for Hyperuricemia in Acute Kidney Injury and Chronic Kidney Disease?	A. Ahsan Ejaz, MD, FACP	-	
		Management of Acute Goat and Chronic Hyperuricemia	Robert Wortmann, MD		

### Friday, March 27

TIME	SESSION #	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am	805	Breakfast Symposium: Nephropathic Cystinosis: New Insights and Approaches to Care Supported by an educational grant from Raptor Pharmaceuticals	Chair: Paul Goodyer, MD	° <b>®</b> }	1.5
		New Insights into Pathogenesis and Diagnosis	Minnie Sarwal, MD, MRCP, FRCP, DCH, PhD	-	
		New Approaches to Treatment and Monitoring	Paul Goodyer, MD	-	
		Transitioning to Adolescent and Adult Care	Sandra Amaral, MD, MHS	-	
6:00am – 7:45am	806	Breakfast Symposium: Evolving Management of Hyperphosphatemia in Chronic Kidney Disease Supported by an educational grant from Fresenius Medical Care Renal Therapies Group	Chair: Daniel Coyne, MD	<b>'@</b> }	1.5
		Clinical Obstacles to Controlling Hyperphosphatemi	Stuart Sprague, DO	-	
		Refinement of Dietary Phosphate Restriction	Orlando Gutierrez, MD, MMSc	-	
		Evolution of Phosphate Binders	Daniel Coyne, MD	-	
7:00am – 8:00am		Continental Breakfast in the Exhibit Hall – Visit Posters/Exhibits		<b>io</b> ł	1.0*
8:30am – 10:00am	566	Both Sides of Diabetes			1.5
		What Can I Eat on a Renal Diabetic Diet?	Marion Franz, RD	-	
		Medical Management of Diabetes	Christine Kessler, MSN, ANP	-	
8:30am – 10:00am	269	Hypertension, Lipids and Vitamin D: A Nephrocentric 2015 Update	Chair: Gavin Becker, MD, FRACP, FNKF		1.5
		Blood Pressure Management in CKD in the Era of JNC8	Raymond Townsend, MD, FAHA	-	
		Is HDL Good or Bad in CKD and ESRD Patients?	Hamid Moradi, MD		
		What's New in Vitamin D in CKD?	Joachim Ix, MD		
10:00am – 10:30am		Break			
10:30am – 12:00pm	270	Wolves in Sheep's Clothing: Drugs and the Risk of Community Acquired AKI	Chair: Wendy St. Peter, PharmD, FCCP, FASN, FNKF		1.5
		Risk of Community Acquired AKI	Roy Matthew, MD	_	
		RAAS Blockade in CKD: A Delicate Balance	Stephen Seliger, MD	_	
		Other Wolves in the Pack: Focus on Over-the-Counter NSAIDs Use	Darren Grabe, PharmD		
12:00pm – 2:00pm		Break in the Exhibit Hall (Lunch Served 12:15pm – 1:15pm) – Visit Posters/Exhibits		101	1.0*

## Pharmacist Program

As of February 26, 2015

2:00pm – 3:30pm	272	Acute Kidney Injury	Chair: Sean Bagshaw, MD, MSc, FRCPC		1.5
		Limitations of Creatinine and the Promise of Biomarkers in AKI	Anitha Vijayan, MD		
		Fluids are Drugs: Type, Dose, Toxicity, and AKI	Andrew Shaw, MD		
		Acute Kidney Injury Alerting: Clinical Information	Manish Sood, MD		
		Sniffing			
2:00pm – 3:30pm	273	Hot Topics in Hypertension	Chair: Debbie Cohen, MD		1.5
		Role of SGLT2 and Incretrins for Lowering BP	Rayond Townsend, MD, FAHA		
		Resistant Hypertension	Michael Weber, MD		
		Renal Denervation Update	Debbie Cohen, MD		
3:30pm – 4:00pm		Break			
4:00pm – 5:30pm	274	Diabetic Kidney Disease: Controversies and Consensus	Chair: Katherine Tuttle, MD, FASN, FACP		1.5
		Assessment of Diabetic Kidney Disease and Glycemic Control	Andrew Narva, MD, FACP, FASN		
		Management Strategies for Glycemic Control: How Tight is Tight?	Katherine Tuttle, MD, FASN, FACP		
		Dual RAAS	Adam Whaley-Connell, DO, MSPH, FNKF		
4:00pm – 5:30pm	275	Debate: Atrial Fibrillation and Kidney Disease	Chair: Wolfgang Winkelmayer, MD, ScD, MPH, FASN		1.5
		Introduction and Debate Rules	Wolfgang Winkelmayer, MD, ScD, MPH, FASN		
		Debate: Warfarin for Stroke Prophylaxis in AFib			
		Pro	Peter McCullough, MD, FNKF		
		Con	Manish Sood, MD		
		Novel Anticoagulants Update 2015	Wolfgang Winkelmayer, MD, ScD, MPH, FASN		
5:30pm – 7:00pm		Networking Reception in the Exhibit Hall – Visit Posters/Exhibits		Ť	1.0*
7:00pm – 9:00pm	807	Dinner Symposium: Simplifying the Algorithm: Diagnosis and Treatment of Hyponatremias	Chair: Biff Palmer, MD	<b>IO</b> I	1.5
		Supported by an educational grant from Otsuka			
		America Pharmaceutical, Inc.			
		Hypotonic Hyponatremias: Pathophysiologies	Tomas Berl, MD		
		Managing Hyponatremia: Simplifying the Therapeutic Algorithm	Richard Sterns, MD		
		Managing Hyponatremia: The Role of Vasopressin Antagonists	Biff Palmer, MD		
		Case Study: Managing Hyponatremia in a Patient with SIADH	All Faculty		
7:00pm – 9:00pm	808	Dinner Symposium: The Potassium Challenge in CKD: Managing Acute and Chronic Hyperkalemia Supported by an educational grant from Relypsa	Chair: Robert Toto, MD	<b>'@</b> }	1.5
		Hyperkalemia in CKD: A Clinical Conundrum	Robert Toto, MD		
		Novel Potassium Binders: Clinical Evidence	Peter McCullough, MD, MPH, FACC, FACP, FAHA, FCCP, FNKF		
		Case Study: Managing Chronic Hyperkalemia in a Patient with CKD and Cardiovascular Disease	Kamyar Kalantar-Zadeh, MD, PhD, MPH, FNKF		
			· · · · · · · · · · · · · · · · · · ·		

### Pharmacist Program

As of February 26, 2015

### Saturday, March 28

TIME	SESSION #	SESSION	FACULTY	NOTES	CREDITS
7:15am – 9:00am	809	Breakfast Symposium: Pathogenesis and Management of Nephrotic Syndrome in Primary Podocytopathies Supported in part by an educational grant from Mallinckrodt Pharmaceuticals	Chair: Fernando Fervenza, MD, PhD, FNKF	ήÌ	1.5
		Insights Regarding the Pathogenesis and Evaluation of Nephrotic Syndrome	Laurence Beck, Jr., MD, PhD		1.0* 1.5 1.5 1.5 1.5
		Management of Nephrotic Syndrome: Treatment Strategies and Current Treatment Options	Brad Rovin, MD	-	
		A Case-Based Approach to Management of Nephrotic Syndrome	Fernando Fervenza, MD, PhD, FNKF	_	
8:00am – 11:30am		Break in the Exhibit Hall (Breakfast Served 8:00am – 9:00am) – Visit Posters/Exhibits		<b>†©</b> ł	1.0*
9:30am – 11:00am	276	KEEP Healthy <sup>™</sup> : Insights into CKD Care	Chair: Kerri Cavanaugh, MD, FNKF, and Josef Coresh, MD, PhD, MHS		1.5
		Awareness and the Continued Need for CKD Detection	Beth Piraino, MD, FNKF	-	
		Evolution of the KEEP into KEEP Healthy	Peter McCullough, MD, FNKF	-	
		Insights into KEEP Healthy	Kerri Cavanaugh, MD, FNKF	_	
9:30am – 11:00am	277	Debate: Vaptans/Hyponatremia	Chairs: Lawrence Weisberg, MD, FNKF, and Richard Sterns, MD		1.5
		Overview of the Approach to Hyponatremia	Biff Palmer, MD	-	
		Management of Chronic Hyponatremia: Are Vaptans Now the First Line Treatment?	Mitch Rosner, MD		
		New Approaches to the Acute Management of Hyponatremia	Richard Sterns, MD		
9:30am – 11:00am	289	Late-Breaking Abstract Presentations	TBD		1.5
9:30am – 11:00am	673	TransplantationStart to Finish			1.5
		The Work Up	Erin Carrithers, NP		
		Management and Complications	Barbara Weis Malone, MSN, RN, CFNP, FNKF		
11:00am – 11:30am		Break			
11:30am – 1:00pm	235	Workshop: Evaluation and Management of Depression and Anxiety in CKD	Chair: Fredric Finkelstein, MD, FNKF	• 101	1.5
		Overview of Depression and Anxiety in CKD	Fredric Finkelstein, MD, FNKF	_	
		Diagnosis and Treatment of Depression in CKD	Susan Hedayati, MD	_	
		Diagnosis and Treatment for Anxiety in CKD	Rajnish Mehrotra, MBBS, MD, FNKF		
11:30am – 1:00pm	237	Workshop: Acid-Base and Electrolytes Supported by an educational grant from ZS Pharma	Chair: Lawrence Weisberg, MD, FNKF	• <b>†@</b> }	1.5
		Cases	Biff Palmer, MD	_	
		Cases	Lawrence Weisberg, MD, FNKF	_	
		Cases	Michael Emmett, MD, MACP		
11:30am – 1:00pm	240	Workshop: Onco-Nephrology: Myeloma, Primary Amyloidosis and other Monoclonal Deposition Diseases	Chair: Fernando Fervenza, MD, PhD, FNKF	• '@}	1.5
		Overview of Paraproteinemic Kidney Diseases	Paul Sanders, MD		
		Prognosis and Treatment for Myeloma and Amyloid	Laura Dember, MD		
		Case Presentations	Agnes Fogo, MD		
1:00pm – 1:30pm		Break			
1:30pm – 3:00pm	279	Biosimilars and Other "Similars" in Nephrology: Setting the Course for Uncharted Territories	Chair: Amy Barton Pai, PharmD, BCPS, FASN, FCCP	_	1.5
		Biosimilar ESAS: How Dissimilar are They?	Jay Wish, MD	_	
		Generic IV Iron Forumulations: Black Solutions in a Regulatory Gray Area	Amy Barton Pai, PharmD, BCPS, FASN, FCCP	_	
		Time for a New Direction? Pipeline Agents for Treating Anemia of CKD	Daniel Coyne, MD		

#### NKF 2015 Spring Clinical Meetings Pharmacist Program

As of February 26, 2015

1:30pm – 3:00pm	676	The Cost of Infections		1.5
		Common Infections in CKD Patients	Beth Adams, PA-C	
		Preventing Hospital Readmissions	Debra Hain, PhD, APRN, ANP, GNP- BC	
3:00pm – 3:30pm		Break		
3:30pm – 5:00pm	282	Managing Medications in CKD/ESRD Patients	Chair: Wendy St. Peter, PharmD, FCCP, FASN, FNKF	1.5
		Medication Safety in ESRD: Pharmacoepidemiology Perspective	Tara Chang, MD	
		Starting a Medication Management Program in Dialysis	Maricela Lara-Nevarez, PharmD	
		Health Literacy and Patient Success	Katie Cardone, PharmD, BCACP, FNKF	
3:30pm – 5:00pm	283	Literature Review	Chair: Daniel Weiner, MD, MS, FNKF	1.5
		CVD	Peter McCullough, MD, FNKF	
		Transplant Donation	Amit Garg, MD, PhD, FRCPC, FACP	
		Hypertension	Raymond Townsend, MD, FAHA	

## Sunday, March 29

TIME/ROOM	SESSION #	SESSION	FACULTY	NOTES	CREDITS
8:00am – 9:30am	284	BP Monitoring and Management	Chairs: Mahboob Rahman, MD, and Rajiv Agarwal, MD	_	1.5
		What is the Role of ABPM and Home Blood Pressure Monitoring in CKD	Mahboob Rahman, MD		
		When is the Best Time to Measure BP in a Dialysis Patient?	Rajiv Agarwal, MD		
		Medication Management of BP in Hemodialysis Patients: Is 3x a Week Dosing Appropriate?	Rajiv Agarwal, MD		
8:00am – 9:30am	285	Debate: Cinacalcet for CKD-MBD	Chairs: Gavin Becker, MD, FRACP, FNKF		1.5
		Overview of Secondary Hyperparathyroidism	Connie Rhee, MD	-	
		Pro: Cinacalcet is an Important Option for CKD-MBD Treatment	Stuart Sprague, DO, FNKF	-	
		Con: Cinacalcet is an Expensive Way to Make MBD Labs Look Good	Daniel Coyne, MD	-	
9:30am – 10:00am		Break			
10:00am – 11:30am	680	Update on Bone and Mineral Management		_	1.5
		Update on Bone and Mineral Disease	Geoffrey Block, MD, CCRI		
		Calcium Dilemmas	Christine Kessler, MSN, ANP		
11:30am		Meeting Adjourns			

• Separate Registration and/or Fee Required

 $\overline{\mathbb{T}}$  Cocktail Reception

Meal served

\* A maximum of 1.0 credit only will be awarded for Poster Sessions.